{"DataElement":{"publicId":"2841263","version":"1","preferredName":"Protocol Treatment First Registration Protocol Treatment Arm Assignment Type","preferredDefinition":"the specific treatment regimen or arm, when more than one protocol treatment is described, assigned at the time of first registration.","longName":"2841251v1.0:2841258v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2841251","version":"1","preferredName":"Protocol Treatment First Registration Protocol Treatment Arm Assignment","preferredDefinition":"information related to the specific treatment regimen or arm, when more than one protocol treatment is described, assigned at the time of first registration.","longName":"2425177v1.0:2841249v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2425177","version":"1","preferredName":"Protocol Therapy","preferredDefinition":"A protocol is a rule which guides how an activity should be performed; a set of formal rules used to specify the format of an exchange of data.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C42651:C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol","conceptCode":"C42651","definition":"A rule which guides how an activity should be performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"03E16831-B3E1-6D9B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-11-02","modifiedBy":"ONEDATA","dateModified":"2005-11-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2841249","version":"1","preferredName":"First Registration Protocol Treatment Arm Assignment","preferredDefinition":"Preceding all others in time or space or degree.:The act of listing or recording officially; officially qualified or enrolled.:A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.:Assignment; an undertaking that you have been assigned to do.","longName":"C25509:C25646:C15538:C25426","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"First","conceptCode":"C25509","definition":"Preceding all others in time or space or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Registration","conceptCode":"C25646","definition":"The act of listing or recording officially; officially qualified or enrolled.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assignment","conceptCode":"C25426","definition":"An allotting or an appointment to a particular person or use, or for a particular time or object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"63C49430-B4D7-645A-E040-BB89AD4325B3","latestVersionIndicator":"Yes","beginDate":"2009-02-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-02-25","modifiedBy":"ONEDATA","dateModified":"2009-02-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"63C49430-B4E8-645A-E040-BB89AD4325B3","latestVersionIndicator":"Yes","beginDate":"2009-02-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-02-25","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"ISO compliance","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2841258","version":"1","preferredName":"First Registration Arm Assignment Type","preferredDefinition":"the protocol treatment regimen assigned at the first registration.","longName":"2841258v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"45","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Octreotide plus interferon alpha 2-b","valueDescription":"Interferon Alpha 2 Octreotide","ValueMeaning":{"publicId":"2841260","version":"1","preferredName":"Interferon Alpha 2 Octreotide","longName":"2841260","preferredDefinition":"Encoded by human INFA2 Gene (IFN Alpha Family) and expressed by macrophages, secreted 188-amino acid 21.6 kD (precursor) Interferon Alpha 2 contains the interferon alpha/beta domain, exhibits interferon-alpha/beta receptor ligand activity, and appears to regulate antiviral defense, cell growth, and immune activation. It stimulates the production of a protein kinase and an oligoadenylate synthetase. (from LocusLink, Swiss-Prot, OMIM, and NCI): The synthetic acetate salt of a long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Similar to somatostatin, octreotide suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon Alpha-2","conceptCode":"C26318","definition":"Interferon alpha-2 (188 aa, ~22 kDa) is encoded by the human IFNA2 gene. This protein is involved in antiviral defense, cell-cell signaling, and immune activation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Octreotide","conceptCode":"C711","definition":"A synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"63C49430-B551-645A-E040-BB89AD4325B3","latestVersionIndicator":"Yes","beginDate":"2009-02-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"63C49430-B56A-645A-E040-BB89AD4325B3","beginDate":"2009-02-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-02-25","modifiedBy":"ONEDATA","dateModified":"2009-02-25","deletedIndicator":"No"},{"value":"Octreotide plus bevacizumab","valueDescription":"Bevacizumab Octreotide","ValueMeaning":{"publicId":"2841261","version":"1","preferredName":"Bevacizumab Octreotide","longName":"2841261","preferredDefinition":"A monoclonal antibody that may prevent the growth of blood vessels from surrounding tissue to a solid tumor.: The synthetic acetate salt of a long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Similar to somatostatin, octreotide suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Octreotide","conceptCode":"C711","definition":"A synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"63C49430-B577-645A-E040-BB89AD4325B3","latestVersionIndicator":"Yes","beginDate":"2009-02-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"63C49430-B590-645A-E040-BB89AD4325B3","beginDate":"2009-02-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-02-25","modifiedBy":"ONEDATA","dateModified":"2009-02-25","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"63C49430-B538-645A-E040-BB89AD4325B3","latestVersionIndicator":"Yes","beginDate":"2009-02-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-02-25","modifiedBy":"CAMPBELB","dateModified":"2009-02-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811911","version":"1","longName":"Upper GI","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811961","version":"1","longName":"Protocol/Admin.","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"To which treatment arm was th","type":"Preferred Question Text","description":"To which treatment arm was the patient assigned at initial registration","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"63C4BE7D-3E38-296B-E040-BB89AD435955","latestVersionIndicator":"Yes","beginDate":"2009-02-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-02-25","modifiedBy":"CAMPBELB","dateModified":"2009-02-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}